0.8921
Precedente Chiudi:
$0.89
Aprire:
$0.92
Volume 24 ore:
127.80K
Relative Volume:
0.10
Capitalizzazione di mercato:
$12.61M
Reddito:
-
Utile/perdita netta:
$-29.77M
Rapporto P/E:
-0.0583
EPS:
-15.2954
Flusso di cassa netto:
$-24.23M
1 W Prestazione:
-8.03%
1M Prestazione:
-9.58%
6M Prestazione:
-66.84%
1 anno Prestazione:
-80.52%
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Confronta MBRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MBRX
Moleculin Biotech Inc
|
0.8921 | 13.70M | 0 | -29.77M | -24.23M | -15.30 |
![]()
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks
Moleculin receives Nasdaq non-compliance notice - Investing.com
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN
Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus
Moleculin Biotech Reports Q1 2025 Financial Results - TipRanks
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup - MSN
Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates By Investing.com - Investing.com India
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates - Investing.com
Moleculin Reports First Quarter 2025 Financial Results and Provi - GuruFocus
Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Prog - GuruFocus
Moleculin (MBRX) Advances Phase 3 MIRACLE Trial with Global Progress | MBRX Stock News - GuruFocus
Moleculin Biotech reports Q1 EPS (69c) vs ($2.02) last year - TipRanks
Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Moleculin's AML Treatment Trial Gets Major EU Expansion as Q1 Results Reveal Timeline for Critical Data - Stock Titan
MOLECULIN BIOTECH Earnings Results: $MBRX Reports Quarterly Earnings - Nasdaq
Moleculin Biotech, Inc. SEC 10-Q Report - TradingView
EMA approves Moleculin’s application for Phase IIb/III AML trial - Yahoo
Moleculin expands EU trial for leukemia treatment By Investing.com - Investing.com South Africa
Moleculin Biotech (MBRX) Gains EMA Approval for Pivotal Phase 2B/3 AML Trial | MBRX Stock News - GuruFocus
Moleculin Receives European Medicines Agency Approval to Expand - GuruFocus
Moleculin expands EU trial for leukemia treatment - Investing.com Australia
Moleculin Receives European Medicines Agency Approval To Expand Phase 3 Miracle Clinical Trial - marketscreener.com
Moleculin Biotech’s Annamycin Trial Approved by EMA - TipRanks
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial - The Manila Times
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum By Investing.com - Investing.com India
Moleculin Biotech Cancels Special Meeting Due to Lack of Quorum - Investing.com Australia
Moleculin Biotech Cancels Special Stockholders Meeting - TipRanks
Moleculin Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - Seeking Alpha
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - Seeking Alpha
Moleculin Biotech to Announce Q1 2025 Financial Results - TipRanks
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - The Manila Times
Moleculin Biotech Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non- - GuruFocus
Moleculin Biotech (MBRX) Gains WHO Approval for Annamycin's Non-proprietary Name | MBRX Stock News - GuruFocus
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):